Introduction
The study of biocompatible chemical processes for the preparation of scaffolds is lately attracting much attention. The vast majority of processes devised so far for the achievement of foams and scaffolds (phase emulsion, air bubbling, or use of templates, among others) [1] [2] [3] [4] [5] makes use of solvents and templates. The complete removal of these chemical compounds (which is not a trivial issue) is required prior to any biomedical application. Otherwise, the biocompatibility of the resulting scaffold is poor. Cryogenic processes, based on freezing of water slurries and/or hydrogels and subsequent freeze-drying, have been widely used for scaffold preparation because of the biocompatibility of both the template and the process for template removal. [6] The process consists of the freezing of colloidal aqueous suspensions. The ice formation causes most solutes originally dispersed in the aqueous suspension to be segregated from the ice phase, giving rise to a macroporous structure characterized by "fences" of matter enclosing ice. The scaffolds obtained after subsequent drying (by both simple thawing and freeze-drying) show a macroporosity that corresponds to the empty areas where ice crystals originally resided. The morphology of such macroporosity can be controlled by the freezing conditions, such as the freezing temperatures and/or the sample immersion direction (unidirectional) into the cryogenic liquid, [7, 8] among others. Thus, Mukai et al. reported the preparation of tailored macroporous honeycomb silica structures through the unidirectional freezing of aqueous silica gels in liquid nitrogen, which allows for excellent control of the morphology of the macroporous structure. [9] Unidirectional freezing into liquid nitrogen has also been applied to different gels and colloidal suspensions of inorganic, organic, and hybrid materials for the formation of well-ordered porous monoliths and fibers. [10] Herein, we further explore the variables of the unidirectional freezing process (named ISISA: ice segregation induced selfassembly); the control of these variables allows the morphology of the macroporous structure to be tailored. In particular, we have applied the ISISA process to the formation of poly(vinyl alcohol) (PVA) scaffolds using different freezing rates, polymer contents, and polymer molecular weights. The resulting morphologies were characterized by porous mercurimetry, scanning electron microscopy (SEM), and cryo-etch-SEM. The influence of morphology on the mechanical properties (e.g., tensile strength) of the PVA scaffolds has been evaluated. In this work, we also explore how fine tuning the PVA scaffold morphology allows for better control of drug release in drug delivery applications. [11, 12] PVA is a biocompatible polymer widely used in tissue engineering and drug delivery applica-tions. [13, 14] The controlled release of antibiotics from scaffold structures has been widely demonstrated to be of great utility to reduce the risks of infection after surgery. [15] For this purpose, we have incorporated the antibiotic ciprofloxacin (CFX) [16] into the macroporous structure of PVA scaffolds. CFX is a synthetic fluoroquinolone antimicrobial agent whose primary mechanism of action against microorganisms involves inhibition of topoisomerase IV and DNA gyrase. [17] CFX is active against both Gram-positive and Gram-negative bacteria. We have analyzed the delivery kinetics of CFX entrapped in two PVA scaffolds with extreme morphologies by UV-vis spectrometry. The ability of PVA2-CFX to inhibit the growth of Escherichia coli K-12 (Gram-negative bacteria) in both solution and agar plates has also been studied.
Results and Discussion
As mentioned above, the formation of macroporous PVA structures by the ISISA process resides in the ability to form ice crystals upon the unidirectional immersion of an aqueous PVA solution into liquid nitrogen, that is, by freezing at -196°C. Such a freezing temperature is well below the glasstransition temperature of water (T g of ca. -137°C), so one could expect the formation of amorphous rather than crystalline ice. However, the T g is not an equilibrium transition temperature and, hence, being only quasi-thermodynamic, may vary with experimental conditions. [18] For instance, freezing rates of ca. 10 6°C s -1 are required if one wants to obtain amorphous ice from pure water. [19] Ice crystallization also depends on the presence of impurities in the water, being fully inhibited for pseudoconcentrated solutions (i.e., threshold value varies largely and depends on the nature of the solute). In particular, it has been reported that PVA can retard ice crystallization; the effectiveness of PVA not only depends on the PVA content in the water but also on its molecular weight and degree of hydrolysis. [20] Given that the ice crystal size formed during the ISISA processing of the aqueous PVA solutions ultimately determines the macroporous structure of the resulting PVA scaffolds, we will focus on the study of three main variables in this work; the PVA content, the molecular weight of the PVA, and the freezing rate. Note that, in the present work, the degree of hydrolysis is similar for every PVA (see Experimental) and, hence, will not be a variable under study.
We begin with the study of the morphology when different PVA contents at the starting aqueous PVA solutions are used (see Experimental). Thus, for low PVA contents (ca. 2.5 wt %), the SEM images reveal the formation of a layered architecture in the form of poorly interconnected PVA sheets arranged in parallel layers (Fig. 1 ). The increase of the PVA content (ca. 7.8 wt %) favors the formation of pillars crossing between layers, fully interconnecting the 3D structure. Besides, the size of the porous channels is scaled down, a consequence of the increased difficulty for the ice crystals to form in the presence of impurities (in this particular case, PVA). A further increase of the PVA content results in structures where the porous channels are almost closed; that is, the PVA content reaches values that favor the formation of amorphous (supercooled water) rather than crystalline ice, so that no segregation of matter occurs. Changes in the scaffold morphology when ISISA is applied to sols/gels of different weight content have previously been reported by Nishihara et al. and Deville et al. for silica and hydroxyapatite scaffolds, respectively. [9b,10e] Moreover, we have also reported on the incapability of forming silica macroporous structures upon freezing when the material content in the aqueous gel is ca. 13.5 wt %. [10g] The study was done by cryo-etch-SEM rather than by the ISISA process, but the mechanism behind macrostructure formation is similar; that is, formation of ice crystals and matter segregation. For cryo-etch-SEM experiments, samples are plunge-frozen by im- Figure 1 . SEM (left and middle columns) and cryo-etch-SEM (right column) images of cross-sectioned (perpendicular to the direction of freezing) monolithic PVA scaffolds. The freezing rates were 5.9 and 9.1 mm min -1 and the average molecular weight of the PVA was 72 000 (PVA2) for every ISISA-processed sample. All scale bars are 20 lm. Note that, in some cases, the length of the scale bar changes for better visualization of the scaffold macrostructure.
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mersion in subcooled liquid nitrogen (e.g., liquid nitrogen at vacuum pressure). Under these circumstances, the freezing rate is about 10 4°C s -1 . [21] This freezing rate is far from that needed to obtain supercooled water by freezing of pure water solutions (ca. 10 6°C s -1 ). [19] However, the presence of impurities makes freezing rates of approximately 10 4°C s -1 fast enough to impede the formation of crystalline ice. The sample temperature is subsequently raised to -105°C, which allows exposed ice to vaporize by sublimation (etching). Such a temperature (ca. 32°C above T g ) favors the formation of crystalline ice, which readily frees itself of any dissolved solute. As a result, solutes are concentrated at the surrounding empty areas where the ice originally resided. [22] Thus, the main difference between the ISISA and cryo-etch-SEM processes is "just" the thermal route followed for crystalline ice formation (from room temperature or from subcooled temperatures, respectively). After ice-crystal formation, the processes are analogous. To further corroborate the analogies between both procedures, we have studied PVA solutions with different solid contents by cryoetch-SEM. The right column of Figure 1 shows the morphology of the different solutions at the cryo-etch-SEM. The morphologies obtained by cryo-etch-SEM follow the same pattern as those obtained from ISISA (left column), and there are only slight differences between the domains size where the crystalline ice originally resided (larger for ISISA than for cryo-etch-SEM as a consequence of the thermal route followed for ice-crystal formation).
The above-mentioned results reveal that the PVA content indeed modifies the morphology of the PVA macrostructure. Nonetheless, low PVA contents (e.g., 2.5 wt %) result in scaffolds with poor mechanical properties (see below). Thus, we fixed the PVA content at 7.8 wt % for the study of the next variables for tailoring of the morphology: the freezing rate (e.g., 0.7, 2.7, 5.9, and 9.1 mm min -1 ) and the molecular weight of the PVA (e.g., PVA1, PVA2, PVA3, and PVA4; see Experimental for details). SEM images reveal that for every sample, the macrostructure resulting from ISISA is characterized by well-aligned micrometer-sized pores in the freezing direction ( Fig. 2 ). However, the channel size is strongly dependent on the molecular weights and the freezing rate. This event can already be observed in Figure 2 , but Figure 3 better reflects the large variety of morphologies that can be obtained for different freezing rates and PVA molecular weights. These SEM images reveal a clear tendency regarding the influence of the controlled variables on the porous channel size; that is, it decreases with an increase of either the freezing rate or the molecular weight.
The more noticeable changes of the microchanneled structure are obtained with different freezing rates, in good agreement with the above-mentioned results obtained from cryoetch-SEM ( Fig. 1 ). In particular, the channel size and the thickness of the matter accumulated between adjacent channels of PVA scaffolds processed at a freezing rate of 9.1 mm min -1 strongly differ from those processed at any other freezing rate 
(from 0.7 to 5.9 mm min -1 ). The changes observed in the pore size of the microchannels also affect the thickness of the matter accumulated between adjacent channels, which, ultimately, is supporting the structure. Thus, the larger the microchannel pore size, the larger the accumulation of matter between channels. The microstructural features resulting from freezing at different rates are in good agreement with previous results recently described by Deville et al. [10e] It is stated that slow freezing rates allow the formation of large ice crystals, which ultimately template the microchanneled structure. Meanwhile, fast freezing rates favor supercooling and, hence, impede the formation of large ice crystals, so that the microchanneled structure is scaled down. It is worth noting that PVA scaffolds prepared at freezing rates of 9 mm min -1 also exhibit some radial heterogeneity with two distinguishable microchanneled structures (see Supporting Information, Fig. S3 ), not observed in any other sample (see Fig. S4 ). Radial heterogeneity occurs because of the occurrence of two opposite features. On the one hand, the use of a fast freezing rate further approaches the supercooled regime and even smaller ice crystals (than for freezing rates of 5.9 mm min -1 ) are formed. In this case, the morphology of the PVA scaffold core is closer to that observed by cryo-etch-SEM (compare to SEM image shown in Fig. 1 , left column). On the other hand, and taking into account the low heat capacity and thermal conductivity (latent heat) of liquid nitrogen, there is a limit on the sample mass that nitrogen is capable of supercooling. Above that limit, a nitrogen vapor barrier is formed around the sample (e.g., the Leidenfrost effect), restricting the rate at which heat is withdrawn from the sample and determining the formation of large ice crystals at the outer shell of the monolith.
The microstructural features observed with changes in the PVA molecular weight must also be ascribed to the ability to form ice crystals. Recent work on the inhibition of recrystallization of ice grains by the presence of PVA reveals that the effectiveness in inhibiting ice crystal formation increases with the molecular weight of the PVA. [20] The ability for ice-crystal growth in the presence of any solute depends on the adsorption and desorption balance of such a solute on the surface of the ice crystal. Irreversible adsorption would completely stop icecrystal growth while full desorption would allow for free crystal growth so that one can assume that adsorption onto ice is a dynamic equilibrium. For a particular solute (PVA, in this case), the effectiveness in inhibiting ice-crystal growth is only related to the extent of coverage of the ice surface area by such a solute. Thus, PVA molecules of higher molecular weight cover larger ice surface areas than PVA molecules of lower molecular weight. Nonetheless, and as mentioned above, the influence of the PVA molecular weight (within the range studied in this work) on the morphology is limited as compared to that obtained by the use of different freezing rates.
Mercurimetry data corroborates the above-described features observed by SEM. The skeletal density and porosity of PVA2 exhibit unmodified values (within experimental error) for freezing rates ranging from 0.7 to 5.9 mm min -1 , but a noticeable decrease of both parameters is observed for freezing rates of 9 mm min -1 (see Table 1 ). PVA4 scaffolds frozen at dif-ferent rates also show similar behavior. Porosity decrease is a consequence of the above-mentioned impeded formation of large ice crystals for freezing rates of 9 mm min -1 . The formation of small ice crystals (or eventually of amorphous ice) makes the matter accumulated between adjacent microchannels less densely packed, as revealed by the decrease in skeletal density. The low skeletal density (below the density value of amorphous PVA, 1.269 mg mL -1 ) is actually indicating the presence of small pores (ca. 300 nm and below) within the material (see Fig. S5 ). Bulk density remains unchanged (within experimental error) within the whole range of freezing rates, as corresponds to samples with identical PVA content. The PVA content (mostly from 2.5 to 7.8 wt %) indeed has a noticeable 
effect on bulk density, skeletal density, and porosity. Meanwhile, mecurimetry data for ISISA-processed PVA scaffolds at similar freezing rates (0.7 or 5.9 mm min -1 ) but with different molecular weights show a smooth evolution of bulk and skeletal density (e.g., increase from PVA1 to PVA4), while porosity does not undergo significant changes. Variations in skeletal density could be ascribed to the degree of crystallinity of different samples. To elucidate this issue, we performed differential scanning calorimetry (DSC) measurements for different PVA scaffolds (Fig. S6) . The degree of crystallinity of PVA scaffolds from DSC (X DSC ) was determined as the ratio between their heat of fusion (DH m , normalized for the mass of the polymer in the gel) and the thermodynamic enthalpy of melting of a 100 % crystalline PVA (DH 0 m ). [23] Thus, the degrees of crystallinity in Table 2 show the typical differences for PVA samples with different molecular weights; [23] no significant differences for scaffolds processed at different freezing rates is seen. The X-ray diffraction (XRD) pattern of our PVA scaffolds (Fig. S7 ) always exhibits (for every sample, independent of the molecular weight or freezing rate used for ISISA) two well-defined peaks centered at approximate 2h values of 28°and 41°(corresponding to the diffraction reflections of partially crystalline PVA), in good agreement with previous results on lyophilized PVA samples. [24] This result corroborates the presence of a significant amount of crystalline PVA aggregates, albeit far from 100 % crystalline PVA. The absence of significant variations in the degree of crystallinity of different PVA scaffolds found by DSC and XRD indicate that the observed changes in skeletal density should actually be ascribed to the existence of small pores within the PVA matter that holds the scaffold structure together (see Fig. S5 and inset of Fig. S4 ).
Differences in morphology should also be translated into the mechanical properties of the scaffolds. For this purpose, the tensile strength of PVA scaffolds with different morphologies was obtained from the stress-strain curves (inset of Fig. 4 ). Figure 4 shows the evolution of the tensile strength with the morphology of the sample. Clearly, the tensile strength increases with the PVA content used for the formation of the scaffold macrostructure (Fig. 4a ). The increase of tensile strength is also noticeable (reaching values close to 4 MPa) for samples with wider pore channels and a large accumulation of matter in the channel walls, which result from the use of PVA with increased molecular weight or slower freezing rates ( Fig. 4b  and 4c , respectively). High values of tensile strength are indicative of bulky character enhancement for those samples with thicker walls. Note that the tensile strength for bulk PVA without macrostructural defects ranges from 20 to 80 MPa (depending on processing, crystalline or amorphous polymer character, and polymer molecular weight, among other variables), [25] while it does not reach values above 1 MPa for macroporous PVA. [26] Note that the enhanced mechanical properties described in this work must be ascribed to the unidirectional microchanneled structure.
As mentioned in the Introduction, the utilization of carriers for local antibiotic release is a very important aspect in the fields of therapeutic and orthopaedic surgery, because meticulousness and surgical precision are not able to guarantee the 
absence of infectious microorganisms. For this purpose, we have studied the controlled release of the antibiotic CFX entrapped within the structure of the PVA scaffolds. Generally, a drug-release pattern depends on many factors, including drugbinding affinity, the rate of hydration of the polymeric material, the molecular weight. Among the different samples studied in this work, PVA scaffolds obtained from the use of PVA materials with different molecular weights and/or processed at different freezing rates seem the most suitable (in terms of morphology) for drug delivery and controlled release purposes. Among them, we decided to discard the use of PVA samples with different molecular weights, given that PVA1 and PVA4 were unsuitable for controlled CFX release (the former was readily soluble in water regardless of the freezing rate used for processing [27] and the latter did not allow the homogeneous incorporation of CFX; i.e., CFX precipitation within the PVA solution occured heterogeneously for PVA4), while CFX release from PVA2 and PVA3 (Fig. S8 of the Supporting Information) is similar, as is their morphology (see Fig. 3 ). Under these circumstances, we just focused on the study of the kinetic release from PVA scaffolds obtained by the processing of identical PVA solutions; that is, identical both in terms of the PVA molecular weight (e.g., 72000, PVA2) and its weight percent in the starting solution for the ISISA process (7.8 wt %); at freezing rates that provide the largest differences in morphology (e.g., 0.7 and 9.1 mm min -1 , see Fig. 3 ).
In the absence of further external stimuli, the mechanisms governing controlled drug release in polymers are basically delayed dissolution and diffusion control. [28] Polymer chains, such as those in a crosslinked hydrogel, form the diffusion barrier that partially inhibits drug-molecule diffusion within an aqueous solution. The barrier to diffusion indeed decreases by swelling of the hydrogel. In the realm of degradable polymers, there exists another type of release control based upon the mechanism of polymer degradation and/or erosion. On the basis of the experimental release patterns shown in Figure 5 and the above explanations, the fast kinetic observed for the drug entrapped in PVA scaffolds processed at a freezing rate of 9.1 mm min -1 must be ascribed to erosion, which refers to depletion of material (e.g., dissolution). [29] It is noteworthy that PVA (in bulk form) is neither degradable nor soluble at the physiological conditions used for CFX release (e.g., water solutions at 37°C), but it can be eroded when it is processed in the form of a widely open structure with a large porous surface area, that is, in the form of a scaffold. This feature is indeed corroborated by the significant loss of scaffold matter occurring after release experiments (PVA weight loss ca. 60 %; see also monolith pictures in Fig. 5 and Fig. S3 ). Note that the walls of matter supporting the PVA scaffold structure processed at freezing rates of 9.1 mm min -1 are extremely thin (see SEM images in Fig. 3) . Moreover, the low skeletal density obtained from mercurimetry (well below the density of amorphous PVA) indicates that the matter is not densely packed. The combination of these two features indeed favors erosion. The matter remaining around the external perimeter of the monolith is microstructurally different from that shown in Figure 3 and, hence, does not overcome erosion (see Supporting Information, Fig. S3 ). Meanwhile, decelerated kinetics for drug release is observed for PVA2-CFX5 processed at freezing rates of 0.7 mm min -1 (Fig. 5 ) because of the thicker fences that form the scaffold structure; that is, the accumulation of matter between adjacent channels for the scaffold processed at this freezing rate is much larger (see SEM images) and confers an enhanced bulky character to this sample (see skeletal density values measured by mercurimetry). In this case, erosion is limited (the PVA weight loss after release experiments is ca. 20 %) so that the preferred mechanism for drug release must be polymer hydration, swelling, and drug dissolution, which ultimately slows down the kinetic release. The CFX release profiles observed for PVA2 processed at freezing rates of 2.7 and 5.9 mm min -1 (Fig. S8 of the Supporting Information) show few differences as compared to PVA2 ISISA-processed at 0.7 mm min -1 . The PVA weight loss observed for these samples after release experiments (ca. 40-50 %) indicates more erosion than for PVA2 ISISA-processed at 0.7 mm min -1 , but pictures of monoliths (Fig. S8) reveal quite a different situation to that observed for PVA2 ISISA-processed at 9.1 mm min -1 : complete erosion of the internal section of the monolith (Fig. 5 ). The increase of CFX loaded into the scaffold (PVA2-CFX10 versus PVA2-CFX5 samples) does not alter the kinetic release (thanks to the incorporation of CFX in the form of crystalline needles; see Experimental); the PVA2-CFX10 release extended for longer periods of time because of the larger amount of entrapped CFX (Fig. 5 ). PVA2-CFX10 samples are of special interest for temporal control, where drug delivery systems aim to deliver the drug over an extended duration or at a specific time during treatment.
Finally, we have tested the ability of PVA2-CFX5 to kill bacteria (E. coli, in this particular case) by the controlled release CFX. For this purpose, we have studied the growth-inhibition Figure 5 . Kinetics of CFX release from PVA2 scaffolds prepared at freezing rates of 0.7 (squares) and 9.1 mm min -1 (circles). Experiments were conducted on PVA2-CFX5 and PVA2-CFX10 scaffolds containing 5 (open symbols) and 10 mg (solid symbols) of CFX, respectively. Dashed lines indicate 100 % CFX release. Pictures of monolithic PVA2-CFX5 scaffolds prepared at freezing rates of 0.7 (a) and 9.1 mm min -1 (b) are also shown in the insets. Before release, the images show lyophilized gels. After release, wet gels are shown. In this latter case, erosion can be seen in the PVA2-CFX5 scaffold prepared at a freezing rate 9.1 mm min -1 .
effects of PVA2-CFX5 and PVA2 scaffolds (the latter used as negative control) on E. coli in both solution and agar plates. Figure 6a shows that PVA2-CFX5 completely inhibited the growth of E. coli in solution: the inoculated culture medium remains transparent (left flask with negligible optical density) after an overnight incubation at 37°C in contrast to the culture that contained a PVA2 monolith lacking CFX (right flask, negative control with optical density of 0.27 for a tenfold diluted sample), which corresponds to a turbid culture medium in which bacteria growth is not inhibited. Confocal microscopy images confirm the absence of bacteria in the PVA2-CFX5 scaffold, while bacteria efficiently colonized the PVA2 scaffold lacking CFX (Fig. 6b and c, respectively) . [10i] The experiments were conducted with CFX doses well above the minimum inhibitory concentrations (MIC) of CFX, but identical results were obtained with CFX concentrations close to MIC (see Fig. S9 ). Culture plates corroborate the above-observed behavior; bacterial growth was fully inhibited all around the fine powder of PVA2-CFX5 scaffold deposited onto the solidified agar inoculated with E. coli (delineated by the blue line in Fig. 6d ), while no significant signs of growth inhibition were observed when the powder deposited onto the agar plate corresponded to a PVA2 scaffold lacking CFX (Fig. 6e ).
Conclusions
In summary, this work demonstrates the ability of unidirectional freezing (i.e., the ISISA process) for preparation of monolithic scaffolds with a microchanneled structure, the morphology of which can be finely tailored. The engineered scaffolds exhibit good mechanical properties, high porosity, mostly composed of well-aligned microchannels, and high surface area/volume ratios, which, overall, makes them highly suitable for delivery and controlled release of drug substances. This is indeed the case for an antibiotic such as CFX, whose controlled release can be governed for different periods of time. The release kinetic is governed by the morphology of the PVA scaffolds resulting from the use of different freezing rates in the ISISA process. The extremely different morphology of the scaffolds determines two different mechanisms for controlled release; one (e.g., PVA2-7.8 wt % frozen at 9 mm min -1 ) mainly based on scaffold erosion, the other (e.g., PVA2-7.8 wt % frozen at 0.7 mm min -1 ) based on scaffold hydration, swelling, and dissolution of the entrapped drug. Thus, fast release kinetics (ca. 50 % in just 45 min) are achieved for PVA scaffolds prone to erosion, while the release for PVA scaffolds with an enhanced bulky character can be extended for longer periods of time (complete release needs more than 30 h). Moreover, the PVA scaffold can be loaded with different drug concentrations, so we can easily select the proper drug dose to be higher than MIC but without any risk of toxic overdoses. [16] In vitro experiments have also demonstrated the ability of PVA2-CFX to inhibit the growth of E. coli in different culture media.
Experimental
Materials: Poly(vinyl alcohol)s (PVA1, PVA2, PVA3, and PVA4) of different weight-average molecular weights (13 000-23 000, 72 000, 89 000-98 000, and 130 000, respectively) and with a similar degree of hydrolysis (0.98, 0.98, > 0.99, and > 0.99, respectively) were purchased from Sigma-Aldrich and used as received. Ciprofroxacin (CFX) was purchased from Normon Inc. (CIC2071) and double-lyophilized prior use. Buffered solutions were freshly prepared with K 2 HPO 4 and NaOH from Aldrich. Water was distilled and deionized.
Preparation of PVA Scaffolds: Homogeneous solutions of PVA1, PVA2, PVA3, and PVA4 were prepared by addition of different amounts of PVA (ranging from 2.5 to 10 wt %) to 100 mL of hot (at ca. 80°C) water. Solutions were stirred for 3 h, keeping the temperature at 80°C. Every solution (1 mL) was collected into insulin syringes and dipped at different rates (nominal; 0.7, 2.7, 5.9, and 9.1 mm min -1 ) into a cold bath maintained at a constant temperature of -196°C (liquid nitrogen). The visual observation of the ice-front progress provided a more realistic measurement of the freezing rate. Thus, the ice front progressed at the nominal freezing rate for fast freezing rates (e.g., 5.9 and 9 mm min -1 ). Meanwhile, the ice-front progress differed from nominal for slow freezing rates (e.g., 0.7 and 2.7 mm min -1 ), depending on . Picture (a, left) shows a culture medium in which bacteria growth was inhibited (no turbidity) by release of CFX from the PVA2-CFX scaffold. In the presence of a PVA2 scaffold lacking CFX, bacterial growth was efficient and the culture medium became turbid (a, right). Red arrows point to PVA2-CFX and PVA2 monoliths immersed in the non-turbid and turbid media, respectively. Confocal fluorescence microscopy images of PVA2-CFX (b) and PVA2 (c) monoliths were obtained after soaking for 24 h in the bacteria culture medium. Depth of focus is 4 lm. Scale bar is 20 lm. Picture of finely ground PVA2-CFX (d) and PVA2 (e) scaffolds deposited on top of an agar bacteria culture medium. Blue line in (d) delimits the zone where bacteria growth is inhibited by CFX while no inhibition is observed in (e) for PVA2 scaffolds. Red arrows point to powder of PVA2-CFX and PVA2 scaffolds on the agar plate. PVA2-CFX and PVA2 scaffolds were prepared at freezing rate of 0.7 mm min -1 .
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the length of the immersed syringe; that is, ice front progress was faster than the nominal freezing rate at the beginning of the freezing process (the bottom portion of the monoliths), but it reached a stationary value (e.g., nominal) at the upper portion of the monoliths (the portion used for experiments). The unidirectionally frozen samples were freezedried using a ThermoSavant Micromodulyo freeze-drier. The resulting monoliths kept both the shape and the size of any container, in which the suspensions were eventually collected prior to freezing (in this particular case, polypropylene insulin syringes with dimensions: 7.5 cm long and 0.5 cm in diameter) [10] . As recently described by Deville et al. [10e] , the resulting scaffolds exhibited a lamellar structure at the upper zone of the monoliths, resulting after freeze-drying. Characterization and experiments were always conducted on monolith portions of such an upper zone.
Preparation of PVA2-CFX Scaffolds: Lyophilised CFX (50 and 100 mg) was added to 10 mL of 7.8 wt % aqueous PVA2 solutions. Figure S1 shows the crystalline needles of CFX homogeneously suspended into the PVA2 solution. Every suspension (PVA2-CFX5 and PVA2-CFX10) was collected into insulin syringes and frozen at two different rates (0.7 and 5.9 mm min -1 ). The ISISA process followed as described above. CFX crystalline needles helped to incorporate increased CFX concentrations without modifying the morphology of the resulting PVA2-CFX scaffolds (Fig. S2 ). The latter allowed comparable release kinetics for different CFX concentrations to be obtained [30] .
In Vitro Release Kinetic Experiments: Phosphate-buffered solution (PBS, 0.1 M, pH 7.4) was used as a medium for drug-release tests. Similar amounts of every PVA2-CFX scaffold were placed into a tube containing 5 mL of PBS buffer and soaked at 37°C to allow CFX to diffuse out of the scaffold into the PBS buffer. The buffer was periodically removed (time intervals selected to fit sink conditions) and replaced by fresh PBS buffer to continue the release test. The removed PBS buffer was filtered through a 0.45 lm filter (Albeit-JCR regenerated cellulose) and analyzed by UV-vis spectrometry. The release of CFX was quantified by the measurement of the intensity of the absorbance peak allocated at 276 nm (e = 28 400 M cm -1 ). Background readings were obtained from PVA2 scaffolds without CFX. Experiments were conducted in triplicate.
Antibacterial Property of PVA2-CFX Scaffolds: Escherichia coli K-12 (E. coli) was selected as the test microorganism. The bacterial strain of E. coli used in this work was genetically engineered to express a fluorescent protein (green fluorescent protein, GFP) in response to an inducer [31] . Sterile (e.g., UV-irradiated) PVA2 and PVA2-CFX scaffolds were soaked into a suspension of E. coli in culture medium. The culture medium was composed of 20 mL of M9 minimal salts medium (58 mM Na 2 HPO 4 . 12 mM H 2 O, 22 mM KH 2 PO 4 , 8 mM NaCl, 18 mM NH 4 Cl, 2 mM MgSO 4 , 0.1 mM CaCl 2 , 6 pM Vitamine B1) [32] supplemented with 30 mM glucose as the carbon source. Bacteria were allowed to grow for 24 h at 37°C. The antibacterial properties of PVA2-CFX scaffolds were also tested on an agar medium. For this purpose, E. coli cells were spread onto Petri dishes containing LB growth media solidified with 1.5 wt % agar [32] . Finely ground PVA2-CFX and PVA2 (as negative control) scaffolds were deposited on the center of the solidified agar. Plates were incubated for 24 h at 37°C and the formation of a halo (indicative of growth inhibition) around the deposited scaffolds was directly visualized. All measurements were performed in triplicate.
Sample Characterization: Sample morphologies were investigated by scanning electron microscopy (SEM) and cryo-etch-SEM using a Zeiss DSM-950 instrument. Cryo-etch-SEM experiments were conducted as described elsewhere [10g, 33] . Briefly, PVA solutions were placed into a specimen holder, which was plunged into sub-cooled liquid nitrogen, and then transferred to a preparation unit via an air lock transfer device. The frozen specimens were cryofractured and transferred directly via a second air lock to the microscope cold stage, where the temperature was raised to -105°C in ca. 5 min. The samples were etched for 2 min at this temperature, and the etched surfaces resulting after ice sublimation were sputter-coated with gold in the preparation unit. Samples were subsequently transferred onto the cold stage (at -135°C) of the scanning electron microscope chamber for observation (experimental conditions: acceleration potential, 15 kV; working distance, 10 mm; and probe current, 5 to 10 nA). Bulk and skeletal density, and porosity data were obtained using a Micromeritics Autopore II 9220 mercury porosimeter. Differential scanning calorimetry (DSC) analysis was carried out in a Seiko DSC 220CU calorimeter by loading the samples on hermetically sealed aluminum pans. DSC scans consisted of one heating/cooling cycle in a temperature range between 20 and 250°C at a scan rate of 10°C min -1 [34] . XRD patterns were obtained by using a Phillips 1700 difractometer using the Cu Ka radiation (step size, 0.05°; counting time, 6 s). Mechanical properties were analyzed in triplicate using an Instron tensile tester at a strain rate of 1 mm min -1 . Specimens were monolithic samples of cylindrical shape with 4 mm diameter and 10 mm gauge length. UV-vis spectrometry analyses were performed in a Variant Cary 4000 spectrophotometer. Confocal fluorescence microscopy was performed with a Radiance 2100 (Bio-Rad) Laser Scanning System on a Zeiss Axiovert 200 microscope. Confocal fluorescent images of PVA scaffolds were taken from the external surface of the scaffold up to a depth of 30 lm [10i].
